Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 12/20 | 0.51 |
| ▸ | RXRB | P28702 | 12/20 | 0.51 |
| ▸ | RXRG | P48443 | 9/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5216370 | 0.90 | HDAC6 (0.46) | RXRARXRBRXRGNR4A2HDAC6 | |
| SCHEMBL5213384 | 0.89 | RXRA (0.47) | RXRARXRBRXRGNR4A2FGFR1 | |
| SCHEMBL5206515 | 0.89 | MKNK1 (0.44) | RXRARXRBRXRGNR4A2FGFR1 | |
| SCHEMBL5211644 | 0.89 | RXRA (0.50) | RXRARXRBRXRGNR4A2FGFR1 | |
| SCHEMBL5210562 | 0.84 | HPGD (0.42) | RXRARXRBRXRGFGFR1 | |
| SCHEMBL5212489 | 0.83 | RXRA (0.43) | RXRARXRBRXRGNR4A2FGFR1 | |
| SCHEMBL5211394 | 0.83 | HDAC6 (0.42) | RXRARXRBRXRGNR4A2HDAC6 | |
| SCHEMBL5213449 | 0.83 | RXRA (0.43) | RXRARXRBRXRGNR4A2FGFR1 | |
| SCHEMBL5213245 | 0.81 | HTT (0.46) | RXRARXRBFGFR1HDAC6PLK1 | |
| SCHEMBL5211580 | 0.81 | RXRA (0.42) | RXRARXRBRXRGHDAC6EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | RXRA 1231/4885RXRB 1269/4885RXRG 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.